Close
American Drug Delivery & Formulation Summit
Xylem

Genetic Technologies Limited Appoints Dr. Mervyn Cass as Company Director

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Shilpa Biologicals Launches Integrated ADC Production Site in India

Shilpa Biologicals Ltd, a subsidiary of Shilpa Medicare Ltd,...

CPHI Milan 2026 Unveils Dedicated Innovation Hubs for Pharma Manufacturing

CPHI Milan 2026, recognized as a premier global gathering...

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Pangaea Data (Pangaea), a provider of a guideline-configured AI...
- Advertisement -

The Board of Directors of Genetic Technologies Limited has with great pleasure appointed Dr. Mervyn Cass as a non-executive Director of the Company. Dr. Cass is a practicing medical practitioner and, after 28 years as the senior partner in an occupational medical practice in Port Melbourne, accepted the appointment as Medical Director of a plastic surgery centre in 1996.ย  He was the founding Chairman of the Australasian Occupational Medical Group and was a Director of Wolfe Research Pty. Ltd., a private medical biotech company associated with RMIT University. He has been an advisor to the Victorian Government on Workersโ€™ Compensation and Radiological Standards in general practice. Dr. Cass is currently an executive member of the Jewish Community Council of Victoria, the roof body of the Victorian Jewish Community.ย 

The Companyโ€™s Chairman Mr. Sid Hack said, โ€œThe Directors of Genetic Technologies are delighted that Mervyn has agreed to join the Board. His substantial experience in the fields of medicine, womenโ€™s health and restorative surgery will be of great practical and immediate value in the growth and development of the Companyโ€™s cancer diagnostics business. We very much look forward to working with Mervyn at this important time in the history of the Company.โ€

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Shilpa Biologicals Launches Integrated ADC Production Site in India

Shilpa Biologicals Ltd, a subsidiary of Shilpa Medicare Ltd,...

CPHI Milan 2026 Unveils Dedicated Innovation Hubs for Pharma Manufacturing

CPHI Milan 2026, recognized as a premier global gathering...

Sanofi Partners with Pangaea for AI-Driven AATD Detection

Pangaea Data (Pangaea), a provider of a guideline-configured AI...

Shilpa Biologicals Launches PartnerPower Platform for CDMOs

Shilpa Biologicals Pvt. Ltd. (SBPL) has introduced PartnerPower Platform,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป